Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of the Effect of Lactisole on the Intestinal Glucose Uptake

This study has been completed.
Information provided by:
University Ghent Identifier:
First received: February 26, 2008
Last updated: April 6, 2009
Last verified: April 2009
Study of the effect of lactisole on glucose uptake

Condition Intervention Phase
Dietary Supplement: lactisole
Other: placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Health Services Research
Official Title: Study on the Effect of Lactisole on the Intestinal Glucose Uptake

Further study details as provided by University Ghent:

Primary Outcome Measures:
  • Differences in glucose uptake rate in lactisole treated subjects versus placebo treated subjects during oral glucose tolerance test [ Time Frame: 5 weeks ]

Secondary Outcome Measures:
  • Differences in blood insulin, glucagon, triglycerides, GIP and GLP-1 in lactisole treated subjects versus placebo treated subjects during oral glucose tolerance test, ECG [ Time Frame: 5 weeks ]

Estimated Enrollment: 10
Study Start Date: March 2008
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
administration of lactisole
Dietary Supplement: lactisole
administration of lactisole followed by placebo
Placebo Comparator: 2
administration of placebo
Other: placebo
administration of placebo followed by lactisole


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male subject, between 18 and 50 years
  • General good health condition

Exclusion Criteria:

  • Overweight (Body Mass Index ≥30)
  • Metabolic disorders
  • History of gastrointestinal disorders
  • Regular (daily) intake of medication
  • Smoking more than 10 cigarettes/day
  • History of drug abuse
  • Exhaustive (> 3 units/day) alcohol consumption
  • Exhaustive (> 5 units/day) caffeine consumption (coffee, tea, cola, or other caffeine based drinks)
  • Recent (in the last 14 days) donation of blood
  • Recent (in the last 2 days) donation of blood plasma
  • Participation in another trial within 4 weeks before the start of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00631293

University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Ghent
Principal Investigator: Luc Van Bortel, MD, PhD University Hospital, Ghent
  More Information

Responsible Party: Dirk Iserentant, PhD, University Ghent Identifier: NCT00631293     History of Changes
Other Study ID Numbers: 2008/103
Study First Received: February 26, 2008
Last Updated: April 6, 2009

Keywords provided by University Ghent:
Healthy volunteers processed this record on April 27, 2017